Publicaciones en las que colabora con Kepa B. Uribe (29)

2024

  1. Aterosklerosiaren fisiopatologia: disfuntzio endotelialetik plakaren hausturara

    Osagaiz: osasun-zientzien aldizkaria, Vol. 8, Núm. 1, pp. 119-132

  2. OptiMo-LDLr: An Integrated In Silico Model with Enhanced Predictive Power for LDL Receptor Variants, Unraveling Hot Spot Pathogenic Residues

    Advanced Science, Vol. 11, Núm. 13

2023

  1. Predictive Modeling and Structure Analysis of Genetic Variants in Familial Hypercholesterolemia: Implications for Diagnosis and Protein Interaction Studies

    Current Atherosclerosis Reports, Vol. 25, Núm. 11, pp. 839-859

2022

  1. Boosting Cholesterol Efflux from Foam Cells by Sequential Administration of rHDL to Deliver MicroRNA and to Remove Cholesterol in a Triple-Cell 2D Atherosclerosis Model

    Small, Vol. 18, Núm. 13

  2. Familial hypercholesterolemia

    Cholesterol: From Chemistry and Biophysics to the Clinic (Elsevier), pp. 501-524

  3. Leu22_Leu23 Duplication at the Signal Peptide of PCSK9 Promotes Intracellular Degradation of LDLr and Autosomal Dominant Hypercholesterolemia

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 42, Núm. 7, pp. E203-E216

2021

  1. (r)HDL in theranostics: How do we apply HDL's biology for precision medicine in atherosclerosis management?

    Biomaterials Science, Vol. 9, Núm. 9, pp. 3185-3208

  2. A systematic approach to assess the activity and classification of pcsk9 variants

    International Journal of Molecular Sciences, Vol. 22, Núm. 24

  3. Kukutxeztula: «gainditutako» gaitz baten itzulera

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 39, pp. 61-78

  4. MLb-LDLr: A Machine Learning Model for Predicting the Pathogenicity of LDLr Missense Variants

    JACC: Basic to Translational Science, Vol. 6, Núm. 11, pp. 815-827

  5. MLb-LDLr: LDLaren hartzailearen aldaeren eragina aurresatekoikasketa automatikoko eredua

    Osasun zientzak: IV. Ikergazte Nazioarteko Ikerteta Euskaraz. 2021eko ekainaren 9, 10 eta . Gasteiz, Euskal Herria.

  6. Molecular mechanisms of lipotoxicity-induced pancreatic β-cell dysfunction

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 357-402

  7. Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 41, Núm. 2, pp. 934-943

2020

  1. Cholesterol efflux efficiency of reconstituted HDL is affected by nanoparticle lipid composition

    Biomedicines, Vol. 8, Núm. 10

  2. Hiperkolesterolemia Familiarra: patofisiologia, diagnostikoa eta tratamendua

    Osagaiz: osasun-zientzien aldizkaria, Vol. 4, Núm. 1, pp. 69-80

  3. MiR-27b modulates insulin signaling in hepatocytes by regulating insulin receptor expression

    International Journal of Molecular Sciences, Vol. 21, Núm. 22, pp. 1-16

  4. Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR

    Scientific reports, Vol. 10, Núm. 1, pp. 1727

  5. Pathophysiology of type 2 diabetes mellitus

    International Journal of Molecular Sciences, Vol. 21, Núm. 17, pp. 1-34

  6. Statin treatment-induced development of type 2 diabetes: From clinical evidence to mechanistic insights

    International Journal of Molecular Sciences, Vol. 21, Núm. 13, pp. 1-25

2019

  1. Erratum: Site-specific O-glycosylation of members of the low-density lipoprotein receptor superfamily enhances ligand interactions (Journal of Biological Chemistry (2018) 293 (7408-7422) DOI: 10.1074/jbc.M117.817981)

    Journal of Biological Chemistry